BDTX Q3 2023 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

BDTXBlack Diamond Therapeutics, Inc.

$126M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$23M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$172M

Total Liabilities

$38M

Stockholders' Equity

$134M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$22M	-8.5%
Net Income	-$23M	-$22M	-6.2%